September 2017

New Indications

Opdivo (nivolumab) is now indicated as monotherapy for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy.

Ozurdex (dexamethasone) intravitreal implant is now indicated for the treatment of macular oedema due to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO); noninfectious uveitis affecting the posterior segment of the eye.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au